Skip to content
An Initiative of AVAC
Search

Resource Library

The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.

Filter By
Multiple filters can be used at once

Showing results 1 - 10 of 104

Selected Filters:
21 October 2024

Building a Comprehensive Approach to HIV Prevention: Strengthening Gender-Based Violence Response in PrEP Services

Experiencing gender-based violence (GBV) hinders access to and effective use of HIV prevention products by those who would benefit most from them, especially adolescent girls and young women. While the introduction of new PrEP products is an exciting development for HIV prevention programs worldwide, optimizing the impact of PrEP choice requires understanding how GBV affects…

Community/Advocacy, Normative Guidance/Policies, Service Delivery

Event
1 October 2024

Expanding Access to Lenacapavir

This United Advocates Network Call, titled Breaking New Ground: Expanding Access to Lenacapavir— Lessons from Dolutegravir and the Future of HIV Prevention, brought together global health experts, community advocates, and civil society organizations to discuss the challenges and opportunities in ensuring equitable access to Lenacapavir.

Community/Advocacy

External Link
20 August 2024

The Long Wait for Long-acting HIV Prevention and Treatment Formulations

This commentary from The Lancet HIV calls on WHO, financial donors, manufacturers, and governments to take coordinated action to make long-acting HIV prevention and treatment available at scale in lower and middle income countries.

Community/Advocacy, Research, Service Delivery

Document
15 August 2024

Let’s Talk LEN: What global advances in HIV prevention mean for Black communities in the US

Groundbreaking results from the PURPOSE 1 trial conducted among cisgender Ugandan and South African women have changed the injectable PrEP global landscape. This webinar will explore the implications of these findings for US Black populations. Moderators: John Meade Jr., Senior Program Manager, Policy at AVAC & Founding Member of PrEP in Black America (PIBA) Leisha…

Community/Advocacy, Research

Event
19 July 2024

Advocates’ Guide to Multipurpose Prevention Technologies (MPTs)

Multipurpose prevention technologies (MPTs) are products designed to simultaneously address more than one sexual and reproductive health concern. This advocates’ guide shows the pipeline of products in development, discusses why MPTs are needed, investment, and what advocates can do to push for MPT development and introduction.

Community/Advocacy, Research

Document
12 July 2024

Empowering Youth in HIV Prevention and Treatment: The role of meaningful youth engagement and innovative, behavioral, and social science-driven approaches

This document outlines the agenda and speaker biographies for a satellite session at AIDS 2024 dedicated to the meaningful engagement of youth in HIV prevention, care, and treatment work, hosted by USAID and the US government’s Bureau of Global Health Security and Diplomacy.

Community/Advocacy

Document
20 June 2024

Establishing and Implementing a Youth Network for HIV Prevention: A case study of meaningful youth engagement in Zimbabwe

This case study, developed by the South-South Learning Network, Global HIV Prevention Coalition, and Insight 2 Implementation, shares four key learnings from Zimbabwe’s experience of setting-up a successful youth network to meaningfully engage young people in designing, developing, delivering and monitoring the HIV prevention response for adolescents and young people. In addition to the English…

Community/Advocacy

Document
14 June 2024

Generic CAB for PrEP Development and Access

This presentation from Medicines Patent Pool explains the process of licensing, developing, and manufacturing generic cabotegravir (CAB) for PrEP, including expected timelines for generic CAB for PrEP availability.

Community/Advocacy

Presentation
7 May 2024

AfroCAB’s Frequently Asked Questions on Cabotegravir for PrEP

This document, produced by AfroCAB, answers frequently asked questions that users may have about cabotegravir (CAB) for PrEP.

Community/Advocacy

Document
2 April 2024

We Can’t End HIV in the United States Without Equitable PrEP Access: Strategies for success

A collaboration between HIVMA, PrEP4All, and The Choice Agenda, this webinar will assess some of the key challenges to delivering PrEP in the United States equitably, including cost, the complexities of our health care system, and other factors that inhibit uptake amongst the most vulnerable communities. Strategies to address these challenges will be offered, with…

Community/Advocacy, Financing & Costing, Normative Guidance/Policies, Service Delivery

Event